EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficacy and safety of azacitidine in pediatric patients with newly diagnosed advanced myelodysplastic syndromes before hematopoietic stem cell transplantation in the AZA‐JMML‐001 trial

Franco Locatelli iD, Karin Belander Strålin iD, Irene Schmid, Julián Sevilla iD, Owen P Smith, Marry M van den Heuvel-Eibrink, Marco Zecca iD, Christian M Zwaan, Allison Gaudy, Meera Patturajan, Jennifer Poon, Mathew Simcock und 1 weitere

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.30931 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Franco Locatelli und 12 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Bambino Gesù Children's Hospital, Catholic University of the Sacred Heart, Rome, Italy. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Here we report efficacy, pharmacokinetics, and safety data obtained in treatment‐naive, pediatric patients with newly diagnosed advanced MDS receiving azacitidine in the AZA‐JMML‐001 study. The primary endpoint was response rate (proportion of patients with complete response [CR], partial response [PR], or marrow CR, sustained for ≥4 weeks). Of the 10 patients enrolled, one had an unconfirmed marrow CR and none had confirmed responses after three cycles; the study was therefore closed after stage 1. Azacitidine was well tolerated. The lack of efficacy of azacitidine in pediatric patients with newly diagnosed advanced MDS highlights the need for effective new treatments in these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteMyelodysplastic SyndromesHematopoietic Stem Cell TransplantationHumansChildAzacitidineTreatment Outcome

Stichwörter der Autor:innen

MDSazacitidinehypomethylating agentsmyelodysplastic syndromesmyeloid neoplasiapediatrics

Substanzen

Azacitidine

Autor:innen und Institutionen

  • IRCCS Bambino Gesù Children's Hospital, Catholic University of the Sacred Heart, Rome, Italy.
  • Department of Pediatric Oncology, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Germany.
  • Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
  • NCCS, Children's Health Ireland at Crumlin, Dublin, Ireland.
  • Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

ORCID-Profile: Franco Locatelli, Karin Belander Strålin, Julián Sevilla, Marco Zecca, Charlotte M Niemeyer

Förderung

  • Bristol Myers Squibb

Zitieren

APA

Locatelli, F., Strålin, K. B., Schmid, I., Sevilla, J., Smith, O. P., van den Heuvel-Eibrink, M. M., Zecca, M., Zwaan, C. M., Gaudy, A., Patturajan, M., Poon, J., Simcock, M., & Niemeyer, C. M. (2024). Efficacy and safety of azacitidine in pediatric patients with newly diagnosed advanced myelodysplastic syndromes before hematopoietic stem cell transplantation in the AZA‐JMML‐001 trial. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30931

Vancouver

Locatelli F, Strålin KB, Schmid I, Sevilla J, Smith OP, van den Heuvel-Eibrink MM, et al. Efficacy and safety of azacitidine in pediatric patients with newly diagnosed advanced myelodysplastic syndromes before hematopoietic stem cell transplantation in the AZA‐JMML‐001 trial. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30931

BibTeX
@article{Locatelli2024,
  author = {Locatelli, Franco and Strålin, Karin Belander and Schmid, Irene and Sevilla, Julián and Smith, Owen P and van den Heuvel-Eibrink, Marry M and Zecca, Marco and Zwaan, Christian M and Gaudy, Allison and Patturajan, Meera and Poon, Jennifer and Simcock, Mathew and Niemeyer, Charlotte M},
  title = {Efficacy and safety of azacitidine in pediatric patients with newly diagnosed advanced myelodysplastic syndromes before hematopoietic stem cell transplantation in the AZA‐JMML‐001 trial},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.30931}
}
Kostenlos starten →